Shopping Cart 0
Cart Subtotal
USD 0

Synairgen Plc (SNG) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Synairgen Plc (SNG)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Synairgen plc (Synairgen) is a drug discovery and development company, which focuses on the development of novel drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Its pipeline portfolio includes inhaled interferon beta (IFN-/SNG001) for asthma in Phase II trial; and IFN- (SNG001) for COPD in Phase I trial. The company develops its drugs based on its BioBank platform technology. Its BioBank comprises blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma and COPD. The company uses these resources to develop in vitro and ex vivo models, which can be used for discovering novel drug targets. It discovers and develops the drug targets through early stages and out-licenses them to other pharmaceutical companies for further development and manufacturing. Synairgen is headquartered at Southampton, the UK.

Synairgen Plc Key Recent Developments

Mar 15,2018: Synairgen: Preliminary statement of results for the year ended 31 December 2017

Sep 27,2017: Synairgen: Interim results for the six months ended 30 June 2017

May 17,2017: Synairgen Announces Preliminary statement of results for the year ended 31 December 2016

Mar 10,2017: Synairgen: Additional Positive Data in Lung Fibrosis

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1-About the Company 5

Synairgen Plc-Key Facts 5

Synairgen Plc-Key Employees 6

Synairgen Plc-Key Employee Biographies 7

Synairgen Plc-Major Products and Services 8

Synairgen Plc-History 9

Synairgen Plc-Locations And Subsidiaries 11

Head Office 11

Other Locations & Subsidiaries 11

Section 2-Company Analysis 12

Synairgen Plc-Business Description 12

R&D Overview 12

Synairgen Plc-SWOT Analysis 13

SWOT Analysis-Overview 13

Synairgen Plc-Strengths 13

Synairgen Plc-Weaknesses 14

Synairgen Plc-Opportunities 15

Synairgen Plc-Threats 16

Synairgen Plc-Key Competitors 17

Section 3-Company Financial Ratios 18

Financial Ratios-Capital Market Ratios 18

Financial Ratios-Annual Ratios 19

Performance Chart 21

Financial Performance 21

Financial Ratios-Interim Ratios 22

Financial Ratios-Ratio Charts 23

Section 4-Company's Lifesciences Financial Deals and Alliances 24

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 24

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 25

Synairgen Plc, Recent Deals Summary 26

Section 5-Company's Recent Developments 27

Mar 15, 2018: Synairgen: Preliminary statement of results for the year ended 31 December 2017 27

Sep 27, 2017: Synairgen: Interim results for the six months ended 30 June 2017 28

May 17, 2017: Synairgen Announces Preliminary statement of results for the year ended 31 December 2016 29

Mar 10, 2017: Synairgen: Additional Positive Data in Lung Fibrosis 30

Section 6-Appendix 31

Methodology 31

Ratio Definitions 31

About GlobalData 35

Contact Us 35

Disclaimer 35


List Of Figure

List of Figures

Synairgen Plc, Performance Chart (2013-2017) 21

Synairgen Plc, Ratio Charts 23

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 24

Synairgen Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 25


List Of Table

List of Tables

Synairgen Plc, Key Facts 5

Synairgen Plc, Key Employees 6

Synairgen Plc, Key Employee Biographies 7

Synairgen Plc, Major Products and Services 8

Synairgen Plc, History 9

Synairgen Plc, Subsidiaries 11

Synairgen Plc, Key Competitors 17

Synairgen Plc, Ratios based on current share price 18

Synairgen Plc, Annual Ratios 19

Synairgen Plc, Annual Ratios (Cont...1) 20

Synairgen Plc, Interim Ratios 22

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 24

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 25

Synairgen Plc, Recent Deals Summary 26

Currency Codes 31

Capital Market Ratios 31

Equity Ratios 32

Profitability Ratios 32

Cost Ratios 33

Liquidity Ratios 33

Leverage Ratios 34

Efficiency Ratios 34

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Synairgen Plc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Verona Pharma Plc

Oxagen Ltd

Novartis AG

Napp Pharmaceuticals Ltd

GlaxoSmithKline Plc

Synairgen Plc (SNG)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Synairgen plc (Synairgen) is a drug discovery and development company, which focuses on the development of novel drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Its pipeline portfolio includes inhaled interferon beta (IFN-/SNG001) for asthma in Phase II trial; and IFN- (SNG001) for COPD in Phase I trial. The company develops its drugs based on its BioBank platform technology. Its BioBank comprises blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma and COPD. The company uses these resources to develop in vitro and ex vivo models, which can be used for discovering novel drug targets. It discovers and develops the drug targets through early stages and out-licenses them to other pharmaceutical companies for further development and manufacturing. Synairgen is headquartered at Southampton, the UK.

Synairgen Plc Key Recent Developments

Mar 15,2018: Synairgen: Preliminary statement of results for the year ended 31 December 2017

Sep 27,2017: Synairgen: Interim results for the six months ended 30 June 2017

May 17,2017: Synairgen Announces Preliminary statement of results for the year ended 31 December 2016

Mar 10,2017: Synairgen: Additional Positive Data in Lung Fibrosis

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1-About the Company 5

Synairgen Plc-Key Facts 5

Synairgen Plc-Key Employees 6

Synairgen Plc-Key Employee Biographies 7

Synairgen Plc-Major Products and Services 8

Synairgen Plc-History 9

Synairgen Plc-Locations And Subsidiaries 11

Head Office 11

Other Locations & Subsidiaries 11

Section 2-Company Analysis 12

Synairgen Plc-Business Description 12

R&D Overview 12

Synairgen Plc-SWOT Analysis 13

SWOT Analysis-Overview 13

Synairgen Plc-Strengths 13

Synairgen Plc-Weaknesses 14

Synairgen Plc-Opportunities 15

Synairgen Plc-Threats 16

Synairgen Plc-Key Competitors 17

Section 3-Company Financial Ratios 18

Financial Ratios-Capital Market Ratios 18

Financial Ratios-Annual Ratios 19

Performance Chart 21

Financial Performance 21

Financial Ratios-Interim Ratios 22

Financial Ratios-Ratio Charts 23

Section 4-Company's Lifesciences Financial Deals and Alliances 24

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 24

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 25

Synairgen Plc, Recent Deals Summary 26

Section 5-Company's Recent Developments 27

Mar 15, 2018: Synairgen: Preliminary statement of results for the year ended 31 December 2017 27

Sep 27, 2017: Synairgen: Interim results for the six months ended 30 June 2017 28

May 17, 2017: Synairgen Announces Preliminary statement of results for the year ended 31 December 2016 29

Mar 10, 2017: Synairgen: Additional Positive Data in Lung Fibrosis 30

Section 6-Appendix 31

Methodology 31

Ratio Definitions 31

About GlobalData 35

Contact Us 35

Disclaimer 35


List Of Figure

List of Figures

Synairgen Plc, Performance Chart (2013-2017) 21

Synairgen Plc, Ratio Charts 23

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 24

Synairgen Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 25


List Of Table

List of Tables

Synairgen Plc, Key Facts 5

Synairgen Plc, Key Employees 6

Synairgen Plc, Key Employee Biographies 7

Synairgen Plc, Major Products and Services 8

Synairgen Plc, History 9

Synairgen Plc, Subsidiaries 11

Synairgen Plc, Key Competitors 17

Synairgen Plc, Ratios based on current share price 18

Synairgen Plc, Annual Ratios 19

Synairgen Plc, Annual Ratios (Cont...1) 20

Synairgen Plc, Interim Ratios 22

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 24

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 25

Synairgen Plc, Recent Deals Summary 26

Currency Codes 31

Capital Market Ratios 31

Equity Ratios 32

Profitability Ratios 32

Cost Ratios 33

Liquidity Ratios 33

Leverage Ratios 34

Efficiency Ratios 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Synairgen Plc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Verona Pharma Plc

Oxagen Ltd

Novartis AG

Napp Pharmaceuticals Ltd

GlaxoSmithKline Plc